What’s next for GLP-1 weight loss drugs?

VideoSTATus Report What’s next for GLP-1 weight loss drugs? Pfizer, Amgen, and others look to compete with Novo Nordisk and Eli Lilly Manage alerts for this article Email this article Share this article By Alex HoganJune 18, 2026 Senior Multimedia Producer Alex Hogan[email protected]Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years now. The medications are wildly popular, so it’s no surprise that other pharmaceutical companies like Pfizer and Amgen are trying to grab a piece of the market with similar drugs of their own. In this week’s STATus Report, we’ll see how several pharma companies are trying to compete with Novo and Lilly’s already safe and effective products. We’ll also learn what Novo and Lilly are cooking up in order to stay dominant in the weight loss marketplace. And I drop in for a visit with my STAT colleagues from “The Readout LOUD” podcast for their thoughts on this head-spinning GLP-1 news cycle.Advertisement Amgen, drug development, Eli Lilly, Novo Nordisk, Obesity, Pfizer, Pharmaceuticals, weight loss Submit a correction requestReprints Alex Hogan Senior Multimedia Producer Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Adam's Biotech Scorecard June 18, 2026 STAT Plus: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept The Readout June 17, 2026 STAT Plus: FDA appears open to Moderna’s flu vaccine ahead of adcomm Advertisement Biotech June 17, 2026 STAT Plus: Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval Biotech June 17, 2026 STAT Plus: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industry The Readout June 16, 2026 STAT Plus: ARCH-launched Neumora stops depression program Subscriber Picks